el Institut de Recerca of the Hospital Vall d ’ Hebron (VHIR) starts the greater farmacogenético study on ADHD.
-the study of larger level international nacionale, carried out with the greatest number of patient’s with ADHD: 1,200 patients, 360 patients with ADHD and 360 subjects cont role
-the first study that investigates the genes involves two in ADHD jointly
Рin 76% of cases, and l ADHD has a strong base gen̩ti ca. Knowing the genes of each patient is vital for a personalised treatment
-the results of this study will allow n help in the treatment of children with ADHD
Barcelona, March 2012.- the Institut de Recerca of the Hospital Vall d ’ Hebron (VHIR) has launched the farmacogenético study on ADHD of larger – in our country and abroad -, from the hand of Dr. Josep Antoni Ramos – Quiroga, Coordinator of the comprehensive programme of the attention deficit to the adults (PIDAA) of the service of Psychiatry of the Hospital Universitari Vall d ’ Hebron. The results will be presented in October 2012, within the framework of national and European Congress of Psychiatry and neuropediatrÃa.
The study is intended to confirm that the genetics of each individual determines how the disease manifests how responds to drug treatment and the predisposition to suffer from other disorders. Thus, the results of the DNA analysis of 360 subjects with ADHD and 360 subjects control without ADHD (screening done to confirm absence of clinical pathology), will intersect with clinical data of diagnosis, co-morbidity, response to treatment and adverse effects of patients with ADHD and the absence of clinical control subjects. Genetic analysis used in the study is Neurofarmagen ADHD ®.
According to Mr. Josep Antoni Ramos-Quiroga, the results of the study will provide valuable information to guide treatment in a personalized way. According to the information of the genetic code of each individual, your doctor may prescribe the drug and the most appropriate dose for each patient ”. A fact of particular relevance when it comes to children with ADHD. On the other hand, adds genetic information will help develop prevention programs for those individuals that have predisposition to suffer from other disorders, as the behavior or substance abuse ”.
Genetic analysis Neurofarmagen ® TDAH:
Neurofarmagen ® ADHD is the first genetic analysis that collects information on major genes associated with ADHD, through a saliva sample.
Allows to detect genetic variation present in these genes. Currently, these variations are associated with a greater number of scientific studies that support its importance in the different aspects of ADHD.
Neurofarmagen ® ADHD allows to evaluate aspects such as pharmacogenetics, co-morbidity, susceptibility in order to predict the response to treatment, know if there is a genetic predisposition to any comorbidity in ADHD (conduct and substance abuse disorders) and know the genetic predisposition of the patient to suffer from ADHD.
Disorder attention deficit and Hipe ractividad:
ADHD is a neuropsychiatric disorder beginning in childhood with a prevalence of 5-7% in children (< 18 years) and 2-4% in adults (≥18 years) that is characterized by an excessive inattention and/or hyperactivity and impulsivity. Although it is often considered a problem child, follow-up studies show a persistence of ADHD in adulthood, exceeding 50%.
The etiology of ADHD and other psychiatric disorders is complex. Genetic and later environmental factors appear to increase the susceptibility of developing ADHD. For this reason, in the field of genetics already are being sought new treatment and prevention strategies.
Val l d ’ Hebron Institut de Recerca (VHIR) is an institution of the public sector that promotes and develops the research and innovation of Hospital Universitari Vall bio d ’ Hebron, aimed at finding solutions to the health problems of citizenship and to contribute to the scientific developmentteaching, social and economic in its area of competence.
Laboratories Rubió pioneered the launch of the first methylphenidate on the Spanish market for more than 25 years (Rubifen). Methylphenidate remains the treatment of choice in children with attention deficit and hyperactivity (ADHD). Rubió aims to the pharmaceutical market to offer products of the highest quality and innovation, which has been a constant throughout its history since 1968. With this launch laboratories Rubió returns to be pioneer in the field of ADHD offering a product that represents a breakthrough in the use of personalized medicine.
The new consultation site analisisgeneticotdah.com. A new space to bring the genetics of ADHD health and education professionals, and patients and their families.
